Recurrent or Metastatic Cervical Cancer – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Cervical cancer is outside the pelvis, are classified as persistent/recurrent, metastatic cervical cancer patients. 13% of cervical cancer patients are diagnosed at advanced stages. The 5-year survival rate for metastatic cervical cancer is 16.5%, compared to 91.5% for localized cervical cancer. Cervical cancer is one of the most common malignancies in the female genital tract system. It is the second leading cause of cancer mortality in women aged 20 to 39 years. The prognosis of cervical cancer patients remains poor, especially in metastatic patients. Previous studies have shown that the median survival time of metastatic cervical cancer is only 8-13 months. Due to the poor prognosis, metastatic cervical cancer has become one of the main challenges in the world.

 

The metastatic and recurrent Cervical cancer Single-site metastasis accounted for 68.7%, and multi-organ metastases were relatively rare. Lung metastasis was the most common in single-site metastasis, accounting for 37.9% of all patients, followed by bone metastasis (16.7%) and liver metastasis (12.5%).

Brain metastases were uncommon, only accounted for 1.6%. In patients with multi-organ metastases, lung plus liver metastases and lungs metastases were more common than other multi-organ metastases.

 

The competitive landscape of Recurrent or Metastatic Cervical Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Recurrent or Metastatic Cervical Cancer across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent or Metastatic Cervical Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Recurrent or Metastatic Cervical Cancer– Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          IBI310  Innovent Biologics, Inc   Phase 2

2          AK104  Akeso   Phase 2

3          GB226  Genor Biopharma Co., Ltd.        Phase 2

4          BCD-100           Biocad  Phase 2

5          Cabozantinib     Exelixis Phase 2

6          QL1706 Qilu Pharmaceutical Co., Ltd.     Phase 2

7          SHR-1701         Suzhou Suncadia Biopharmaceuticals Co., Ltd.            Phase 3

8          Cemiplimab       Regeneron Pharmaceuticals      Phase 3

9          VB10.16           Nykode Therapeutics AS           Phase 2

10        LN-145 Iovance Biotherapeutics, Inc.     Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more